Patent | Jotup

Incubate Launches Policy Lab Under New Leadership and Releases IP White Paper

Retrieved on:

星期五, 四月 26, 2024

Competition, Medication, World Intellectual Property Day, Policy, Climate, Intellectual property, Innovation, Axelsen, University, Patent, Patient, Incubation, Private sector, Drug development

In the coming months, Incubate Policy Lab -- the research arm of Incubate -- plans to release additional reports and white papers focused on issues at the intersection of policymaking, venture investment, and drug development.

Key Points:

Accompanying the launch is a new white paper examining the important role intellectual property protections play in biopharmaceutical development.
"We launched Incubate Policy Lab to explore the various impacts policy decisions can have on innovation and investment in the life sciences industry," said Incubate executive director John Stanford.
In the coming months, Incubate Policy Lab -- the research arm of Incubate -- plans to release additional reports and white papers focused on issues at the intersection of policymaking, venture investment, and drug development.
"We're delighted to release this new white paper from Incubate Policy Lab," Axelsen said.

RS BioTherapeutics Adds Jane Wright-Mitchell, Pharm.D., J.D. to Business Advisory Board

Retrieved on:

星期四, 四月 25, 2024

Corporation, University, Clemson University, Pharmacy, General counsel, Champaign–Urbana metropolitan area, Biology, Business, CBD, Principal, Pharming, Patent, Pharmaceutical industry

to the RS BioTherapeutics Business Advisory Board.

Key Points:

to the RS BioTherapeutics Business Advisory Board.
As a member of the Business Advisory Board, Ms. Wright-Mitchell will also serve as fractional General Counsel and Compliance Advisor for RS BioTherapeutics.
Commenting on the addition of Ms. Wright-Mitchell to the Business Advisory Board, Dean Hart, Chief Executive Officer of RS BioTherapeutics said, “I was fortunate to work with Jane while we were both at AcelRx and am thrilled to have her join our Business Advisory Board.
She is registered to practice before the United States Patent and Trademark Office as well as a licensed pharmacist (Illinois).

Breathalyzer Market Booms with Technological Advances; Key to Reducing Alcohol-Related Road Deaths

Retrieved on:

星期四, 四月 25, 2024

Probation Officer, Neil Friedel stated, “In a relatively short period of time the Breath Logix device has become an invaluable device under our 24/7 Sobriety Program. The device allows our clients to autonomously get tested for breath alcohol without the need for our clinic to station a full-time administrator -- its a game changer for us. Our clinic is saving time and money daily with the Breath Logix device deployed in our office. It has quickly become part of our daily routine and work flow process in our clinic.”

Key Points:

With increasing concerns over road safety and stringent legal measures against drunk driving, the demand for breathalyzers has surged globally.
Alcohol-impaired driving remains a critical concern worldwide, contributing significantly to road accidents and fatalities.
According to the World Health Organization, road traffic injuries caused by alcohol impairment are a major public health problem that account for nearly 1.35 million deaths annually.
In the United States alone, about 28% of all traffic-related deaths are attributed to alcohol-impaired driving.

RecycLiCo Secures Additional Patent in India for Key Battery Recycling Processes Including Graphite Separation

Retrieved on:

星期四, 四月 25, 2024

ID4, OTCQB, Graphite, Cobalt, Carbon, Patent, Recycling

The Indian patent follows the form of existing patents previously granted for the same invention in other jurisdictions.

Key Points:

The Indian patent follows the form of existing patents previously granted for the same invention in other jurisdictions.
The patent incorporates 18 claims, including separation of cobalt compounds from cathode materials containing carbon and graphite.
The Company has five (5) additional patent applications relating to lithium-ion battery recycling processes filed globally.
“We are pleased to extend our patent portfolio to include another important emerging market,” said RecycLiCo Chairman Paul Hildebrand.

Cannabix’s Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA

Retrieved on:

星期四, 四月 25, 2024

Weather, Contactless, OTC, DUI, Collection, Calibration, Patent, Patient, Prohibition, Blood alcohol content, Drug

Probation Officer, Neil Friedel stated, “In a relatively short period of time the Breath Logix device has become an invaluable device under our 24/7 Sobriety Program. The device allows our clients to autonomously get tested for breath alcohol without the need for our clinic to station a full-time administrator -- its a game changer for us. Our clinic is saving time and money daily with the Breath Logix device deployed in our office. It has quickly become part of our daily routine and work flow process in our clinic.”

Key Points:

The Company reports that the Breath Logix device has been used daily, collecting over a thousand breath samples autonomously.
The device captures user photos to confirm and record identity, and delivers near instantaneous Blood Alcohol Content (BAC) breath results.
Probation Officer, Neil Friedel stated, “In a relatively short period of time the Breath Logix device has become an invaluable device under our 24/7 Sobriety Program.
The Breath Logix helps organizations save money by deploying an autonomous alcohol screening device which eliminates the need for dedicated alcohol screening administrators using conventional handheld devices.

Cidara Therapeutics Announces Divestiture of Rezafungin to Mundipharma* to Focus on Advancing the Clinical Development of Cloudbreak DFC Pipeline

Retrieved on:

星期三, 四月 24, 2024

Melinta Therapeutics, Sale, Tavarua, Health care, IND, Disease, CDTX, Patent, Patient, CMC, Asset, Intellectual property, DFC, Therapy, SAN, Respect, Pharmaceutical industry

Mundipharma currently has commercial rights to rezafungin outside the U.S. and Japan.

Key Points:

Mundipharma currently has commercial rights to rezafungin outside the U.S. and Japan.
Mundipharma purchased the assets in consideration of its assumption of the ongoing obligation to conduct and fund the ReSPECT Phase 3 clinical trial, the costs of the rezafungin patent portfolio and CMC and regulatory obligations.
The purchased assets also include all rezafungin intellectual property rights, product data, regulatory approvals, rezafungin product and comparator inventory, specified prepaid assets and specified contracts.
*Assets and rights acquired by Napp Pharmaceutical Group Limited, a member of the international network of Mundipharma independent associated companies.

Nauti-Craft, Marine Suspension Inventor, celebrates the Christening of a New Boat, the IMPULSE

Retrieved on:

星期三, 四月 24, 2024

Transfer, Nature, Safety, Economy, News, Land Down Under, Water, Wind, Injury, Patent, EnBW, Baltic Sea, Fatigue, Motion, Interest

On the water, cruising toward the horizon, whether mildly rough waves or stormy conditions will result in fatigue, seasickness, and injuries.

Key Points:

On the water, cruising toward the horizon, whether mildly rough waves or stormy conditions will result in fatigue, seasickness, and injuries.
Dedicated to improving the enjoyment of recreational sailing adventures and the safety of marine workers, Nauti-Craft developed its suspension system that absorbs the impact of waves as they gyrate past.
During the christening, the boat was named IMPULSE, highlighting its purpose of unruffling and sedating the impulses of nature.
More than a pledge to continuously keep elevating the marine industry, this endeavor symbolizes Nauti-Craft’s commitment to meaningful partnerships.

Comstock Completes RenFuel Investment

Retrieved on:

星期三, 四月 24, 2024

Lignin, Cellulosic ethanol, HBO, Partnership, Biorefinery, TRL, Carbon, Biomass, Patent, TPY, SAF, Growth, Renewable energy

VIRGINIA CITY, Nev., April 24, 2024 (GLOBE NEWSWIRE) -- Comstock Inc. (NYSE: LODE) (“Comstock” and the “Company”) today announced the execution of agreements with RenFuel K2B AB (“RenFuel”) wherein Comstock is investing up to $3,000,000 over three years to support commercialization of joint development applications for RenFuel and Comstock complementary renewable fuel technologies, and the continued development of the 100,000 metric ton per year (“TPY”) biorefinery joint venture project in Sweden.

Key Points:

VIRGINIA CITY, Nev., April 24, 2024 (GLOBE NEWSWIRE) -- Comstock Inc. (NYSE: LODE) (“Comstock” and the “Company”) today announced the execution of agreements with RenFuel K2B AB (“RenFuel”) wherein Comstock is investing up to $3,000,000 over three years to support commercialization of joint development applications for RenFuel and Comstock complementary renewable fuel technologies, and the continued development of the 100,000 metric ton per year (“TPY”) biorefinery joint venture project in Sweden.
The applicable investment agreements require the purchase of up to $3,000,000 in 7% senior secured convertible notes funded in quarterly installments of $250,000 for three years.
Comstock has already invested the first $350,000 of this investment.
Comstock holds the exclusive license to RenFuel’s refining technologies in North America, Central America, and South America and available for global distribution.

HeartSciences Announces Grant of Fundamental Patent by the European Patent Office Covering Assessment of Diastolic Function of the Heart Using AI-ECG

Retrieved on:

星期三, 四月 24, 2024

Heart, Blood, European Patent Convention, Hypertrophy, ECG, HSCS, Intelligence, Environment, Patent, Patient, Death, Cardiovascular disease, Growth, Medical device

Diastolic dysfunction (impaired cardiac relaxation) is a sensitive and crucial indicator of overall heart health, providing one of the earliest signs of heart disease, with onset typically occurring before symptoms.

Key Points:

Diastolic dysfunction (impaired cardiac relaxation) is a sensitive and crucial indicator of overall heart health, providing one of the earliest signs of heart disease, with onset typically occurring before symptoms.
Diastolic dysfunction is caused by all common issues that affect heart function or that produce hypertrophy.
Today, measures of diastolic function of the heart need to be assessed in a specialist cardiology environment, typically using echocardiography-based imaging.
The United States Patent and Trademark Office has issued eight utility patents and one design patent to HeartSciences, with patent expiration dates ranging from March 2031 through August 2040.

NaaS Technology and its Parent Company, NewLink, Join the Open Invention Network Community

Retrieved on:

星期三, 四月 24, 2024

Network as a service, Risk, OIN, History, Patent, Intellectual property, Open Invention Network, Growth, Linux, Property management

DURHAM, N.C., April 24, 2024 (GLOBE NEWSWIRE) -- Open Invention Network (OIN), the organization formed to safeguard open source and now the largest patent non-aggression community in history, announced today that NaaS Technology, and its parent company NewLink, have joined as community members.

Key Points:

DURHAM, N.C., April 24, 2024 (GLOBE NEWSWIRE) -- Open Invention Network (OIN), the organization formed to safeguard open source and now the largest patent non-aggression community in history, announced today that NaaS Technology, and its parent company NewLink, have joined as community members.
As the leading new energy asset operator in China, NaaS is reinforcing its commitment to open source as an enabler of advanced charging infrastructure networks.
We are pleased that NewLink and NaaS are committed to patent non-aggression in core Linux and adjacent open source technologies,” said Keith Bergelt, CEO of Open Invention Network.
Linux systems and open source technologies provide support for digitalization, and we appreciate OIN's contribution to reducing the risk of open source software patents around the world.